MOEXIPRIL HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H34N2O7.ClH
Molecular Weight	535.029
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=C(OC)C(OC)=C3

InChI

InChIKey=JXRAXHBVZQZSIC-JKVLGAQCSA-N

InChI=1S/C27H34N2O7.ClH/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32;/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32);1H/t17-,21-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C27H34N2O7
Molecular Weight	498.5681
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15286086https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020312s033lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/14728069
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16620521 | https://www.ncbi.nlm.nih.gov/pubmed/26076923 | https://www.ncbi.nlm.nih.gov/pubmed/9257913 | https://www.ncbi.nlm.nih.gov/pubmed/9079232

Moexipril is a non-sulfhydryl containing the precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. Moexipril hydrochloride is a prodrug for Moexiprilat, which inhibits ACE in humans and animals. The mechanism through which Moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as Moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020312s033lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/14728069	Inhibitor 8297		2.6 nM [IC50]
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26076923	Inhibitor 8297		2.6 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.drugs.com/pro/moexipril.html	Primary		Approved 8429	Moexipril Approved Use Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). Launch Date 1995
Hypertension 567 Sources: https://www.drugs.com/pro/moexipril.html	Primary		Natural Metabolite	Moexipril Approved Use Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). Launch Date 1995

C_max

Value	Dose	Analyte	Population
16 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
24 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
97 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
154 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
98 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
68 μg × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
160 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
328 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MOEXIPRIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
10 h EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOEXIPRILAT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
30% EXPERIMENT https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MOEXIPRILAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11854821/	unhealthy, 55.4 n = 45 Health Status: unhealthy Condition: hypertension Age Group: 55.4 Sex: M+F Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/11854821/	Sources: https://pubmed.ncbi.nlm.nih.gov/11854821/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CES1 22 CES2 28 PEPT1 49 PEPT2 32

Drug as victim

Target	Modality	Activity	Metabolite
CES2 28	substrate 3367 Sources: https://www.nature.com/articles/tpj201542	no
CES1 22	substrate 3367 Sources: https://www.nature.com/articles/tpj201542	yes
PEPT1 49	substrate 3367 Sources: https://www.tandfonline.com/doi/abs/10.1517/17425250903042292	yes	MOEXIPRIL 4
PEPT2 32	substrate 3367 Sources: https://www.tandfonline.com/doi/abs/10.1517/17425250903042292	yes	MOEXIPRIL 4

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1IVG
ABI Chem	AC1Q5QO2
Alfa Chemistry	AP103775140	https://reagents.alfa-chemistry.com/product/moexipril-related-compound-a-cas-103775-14-0-948.html
Alfa Chemistry	103775-14-0	https://www.alfa-chemistry.com/cas_103775-14-0.htm
BOC Sciences	103775-14-0
BioSynth	J-001037	https://www.biosynth.com/en/products/all-products/products/J-001037.html
ChemTik	CTK8E8826
Chemieliva Pharmaceutical Co., Ltd	PBCM1057676
DC Chemicals	DC36859	http://www.dcchemicals.com//product_show-Moexiprilat.html
MuseChem	R044673	https://www.musechem.com/product/R044673.html
NovoSeek	55331
Smolecule	S535918	http://www.smolecule.com/products/s535918
Smolecule	S793772	https://www.smolecule.com/products/s793772
THE BioTek	bt-276722	https://www.thebiotek.com/product/inhibitors/bt-276722
Toronto Research Chemicals	M485320
Toronto Research Chemicals	M485360
Tractus	RT-013928
Wonderchem	WD04LWO
ZINC	ZINC000003789196	http://zinc15.docking.org/substances/ZINC000003789196
eMolecules	45917802

PubMed

Title	Date	PubMed
Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.	1996	8803515
Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats.	1997 Sep	9379124
Moexipril. A review of its use in the management of essential hypertension.	1998 Jun	9617599
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).	1998 May	9643274
Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.	1998 May-Jun	9620109
Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril.	1998 Sep	9825188
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.	2002	11929321
Using ACE inhibitors appropriately.	2002 Aug 1	12182524
Systemic hypertension in postmenopausal women: a clinical approach.	2002 Dec	12419176
Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension.	2002 Feb	11918132
Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.	2002 Jan	11837383
Should perindopril be used to treat patients with heart failure?	2002 May 1	12018799
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.	2003	14728069
Pharmacological and clinical profile of moexipril: a concise review.	2004 Aug	15286086
The influence of relative humidity and temperature on stability of moexipril hydrochloride in solid phase.	2004 Mar-Apr	15493289
[The use of moexipril in postmenopausal women with hypertension and associated changes of bone mineral density].	2005	16091658
[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure].	2005	15759492
Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients.	2005 Jan-Feb	15662286
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
[Moexipril and cardiovascular diseases in women: is there a reason for optimism?].	2006	16883271
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].	2006	16858353
[Investigation of efficacy of cardiovascular drugs in women].	2006	16710266
Moexipril and left ventricular hypertrophy.	2007	17583172
[Clinico-economical efficacy of angiotensin converting enzyme inhibitors in patients with arterial hypertension and ischemic heart disease].	2008	18729835
The Effect of the Dried-Bonito Broth on Blood Pressure, 8-Hydroxydeoxyguanosine (8-OHdG), an Oxidative Stress Marker, and Emotional States in Elderly Subjects.	2008 Nov	19015752
Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.	2008 Nov	18713951
The prince and the pauper. A tale of anticancer targeted agents.	2008 Oct 23	18947424
Determination of antihypertensive drug moexipril hydrochloride based on the enhancement effect of sodium dodecyl sulfate at carbon paste electrode.	2010 Apr 15	20188882
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: A prospective, randomized, open-label, comparative study.	2010 Feb	20606833
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.	2010 Feb	19255851
Identification and determination of antihypertonics from the group of angiotensin-convertase inhibitors by densitometric method in comparition with HPLC method.	2010 Mar-Apr	20369790

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Intravenous

In Vitro Use Guide

After 24 h incubation in serum- and phenol red-free medium (DMEM), neonatal rat cardiac fibroblasts were stimulated with 17b-oestradiol (10^-7 ± 10^-9 M), oestrone (10^-7 ± 10^-9M), angiotensin II (10^-7 M) and moexiprilat (10^-7 M). Cells were harvested after 24 h and cellular proliferation was assessed by BrdU incorporation by use of a colorimetric immunoassay. Moexiprilat (10^-7 M) completely inhibited oestrone-induced cardiac fibroblast growth.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 07:44:11 GMT 2023` Edited by `admin` on `Sat Dec 16 07:44:11 GMT 2023`
Record UNII	Q1UMG3UH45
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOEXIPRIL HYDROCHLORIDE

Official Name

English

UNIVASC

Brand Name

English

MOEXIPRIL HCL

Common Name

English

(3S)-2-[(2S)-N-[(1S)-1-Carboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester, monohydrochloride

Common Name

English

MOEXIPRIL HYDROCHLORIDE [USP-RS]

Common Name

English

UNIRETIC COMPONENT MOEXIPRIL HYDROCHLORIDE

Common Name

English

SPM-925

Code

English

SPM 925

Code

English

MOEXIPRIL HYDROCHLORIDE [MI]

Common Name

English

CI 925

Code

English

RS-10085-197

Code

English

MOEXIPRIL HYDROCHLORIDE COMPONENT OF UNIRETIC

Common Name

English

MOEXIPRIL HYDROCHLORIDE [USAN]

Common Name

English

(3S)-2-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-3-ISOQUINOLINECARBOXYLIC ACID HYDROCHLORIDE

Systematic Name

English

MOEXIPRIL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

MOEXIPRIL HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

CI-925

Code

English

3-ISOQUINOLINECARBOXYLIC ACID, 2-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-, MONOHYDROCHLORIDE, (3S-(2(R*(R*)),3R*))-

Common Name

English

MOEXIPRIL HYDROCHLORIDE [MART.]

Common Name

English

MOEXIPRIL HYDROCHLORIDE [VANDF]

Common Name

English

Moexipril hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247